Neurocrine Biosciences’ (NBIX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $185.00 price target on the stock. HC Wainwright also issued estimates for Neurocrine Biosciences’ Q4 2025 earnings at $1.06 EPS, FY2026 earnings at $4.43 EPS, FY2027 earnings at $7.33 EPS and FY2029 earnings at $14.69 EPS.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group dropped their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a report on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. UBS Group increased their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Wedbush dropped their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $166.90.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $120.69 on Friday. The firm’s 50-day simple moving average is $136.63 and its 200 day simple moving average is $129.31. The firm has a market cap of $12.03 billion, a P/E ratio of 36.68, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a 52 week low of $110.95 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. As a group, equities analysts forecast that Neurocrine Biosciences will post 4.28 earnings per share for the current year.

Neurocrine Biosciences declared that its Board of Directors has approved a share buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Insider Activity at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares of the company’s stock, valued at approximately $346,216.70. This trade represents a 9.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock in a transaction on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the transaction, the director now owns 514,596 shares in the company, valued at approximately $76,911,518.16. This trade represents a 22.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 236,600 shares of company stock valued at $34,348,261 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NBIX. Creative Planning increased its stake in shares of Neurocrine Biosciences by 12.3% in the third quarter. Creative Planning now owns 12,999 shares of the company’s stock valued at $1,498,000 after buying an additional 1,426 shares during the period. Blue Trust Inc. raised its holdings in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the last quarter. Raymond James & Associates raised its holdings in Neurocrine Biosciences by 4.3% during the 3rd quarter. Raymond James & Associates now owns 62,446 shares of the company’s stock worth $7,195,000 after purchasing an additional 2,552 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Neurocrine Biosciences by 42.0% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 9,580 shares of the company’s stock worth $1,104,000 after purchasing an additional 2,832 shares during the period. Finally, Mediolanum International Funds Ltd boosted its stake in shares of Neurocrine Biosciences by 30.0% in the 3rd quarter. Mediolanum International Funds Ltd now owns 59,902 shares of the company’s stock valued at $6,881,000 after purchasing an additional 13,809 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.